Khasraw, M., Singh, K., Violette, M., Corcoran, A., Rlethen, E., Hotchkiss, K., … Fecci, P. (2025). A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma. Research Square. https://doi.org/10.21203/rs.3.rs-5822396/v1

Khasraw, Mustafa, Kirit Singh, Marlene Violette, Anna Corcoran, Emily Rlethen, Kelly Hotchkiss, Chelsea Railton, et al. “A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma.” Research Square, January 22, 2025. https://doi.org/10.21203/rs.3.rs-5822396/v1.

Khasraw M, Singh K, Violette M, Corcoran A, Rlethen E, Hotchkiss K, et al. A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma. Research Square. 2025 Jan 22;

Khasraw, Mustafa, et al. “A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma.” Research Square, Jan. 2025. Manual, doi:10.21203/rs.3.rs-5822396/v1.

Khasraw M, Singh K, Violette M, Corcoran A, Rlethen E, Hotchkiss K, Railton C, Blethen K, Thomas E, Ashley D, Desjardins A, Friedman H, Johnson MO, Friedman A, Keir S, Buckley E, Herndon J, McLendon R, Sampson J, Calabrese E, Lopez G, Grant G, Patel A, Gregory S, Li C-Y, Fecci P. A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma. Research Square. 2025 Jan 22;